About
Tellurium-based Drugs for Treating Wet Macular Degeneration
Feramda Biopharmaceutical develops safe tellurium-based oral drugs that are designed to reduce the number of intravitreal anti-vascular endothelial growth factor injections needed in the treatment of wet age-related macular degeneration, a disease that can cause blindness. Tellurium-based molecules inhibit angiogenesis through a unique mechanism of action that increases angiogenesis inhibitors in the eye and inhibits inflammation.
Identity
| Name | Feramda Biopharmaceutical |
|---|---|
| Slug | feramda-biopharmaceutical |
| Type / kind | startup |
| Source _id | agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICA4JyAxssIDA |
Status
| Status | inactive |
|---|---|
| Status reason | Non Active, Jun 2022 ceased to operate |
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ region/district | Center District |
| HQ city | Kefar Sava |
| HQ address | 4 Kalischer St. Kfar Saba |
Web & social
| Website | https://www.feramda.com/ |
|---|
Classifications
Primary sector Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsMolecules
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business models
B2B
Tags
oral-drugsseniorsbiopharmaceuticalpharmaceuticalsophthalmologyeye-diseasesdrug-discovery
Funding
| Total raised | — |
|---|---|
| Current stage | Seed |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}